Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693 | Chief Financial Officer | August 31, 2026 | September 01, 2026 |
| Spyre Therapeutics, Inc.AGLE · Entity 2649 | Director | June 22, 2023 | June 30, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RHYTHM PHARMACEUTICALS, INC.
Report date August 31, 2026 · Filed September 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 114,024 |
Ending reported balance
After 2026-08-31 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-08-31 · Exercise / conversion · Acquired 57,187 · Balance 176,798 F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. Row 2 · 2026-08-31 · Sale · Disposed 23,072 · Balance 153,726 F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. F2: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $104.04 to $105.03 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-08-31 · Sale · Disposed 11,514 · Balance 142,212 F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. F3: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $105.04 to $106.01 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-08-31 · Sale · Disposed 28,188 · Balance 114,024 F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. F4: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $106.05 to $106.88 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.79 · Expires 2028-02-13 | Direct | 3,813 |
Reported balance
After 2026-08-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-31 · Exercise / conversion · Disposed 57,187 · Balance 3,813 F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026. F5: This option was granted on February 14, 2018 and the shares underlying this option vested in sixteen equal quarterly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise and sales reported in this form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2026.
F2: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $104.04 to $105.03 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $105.04 to $106.01 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $106.05 to $106.88 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: This option was granted on February 14, 2018 and the shares underlying this option vested in sixteen equal quarterly installments.
Spyre Therapeutics, Inc.
Report date June 22, 2023 · Filed June 30, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2033-06-22 | Direct | 1,950,000 |
Reported balance
After 2023-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-22 · Grant · Acquired 1,950,000 · Balance 1,950,000 F1: This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder. F2: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 22, 2023, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option award is contingent upon receiving stockholder approval of the amendment and/or restatement of the 2016 Equity Incentive Plan to increase the number of shares available for issuance thereunder.
F2: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on July 22, 2023, or on the date of the next annual meeting of stockholders, if earlier, subject to the continuing service of the Reporting Person on each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GENESEE & WYOMING INC
Report date December 30, 2019 · Filed December 30, 2019
Section 16 reporting ended · disclosed 2019-12-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common Stock, $.01 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-12-30 transaction · row 1
1 source rowRow 1 · 2019-12-30 · Disposition to issuer · Disposed 11,824 · Balance 0 F1: On December 30, 2019, in connection with the acquisition of Genesee & Wyoming Inc. ("G&W") by Brookfield Infrastructure and GIC, pursuant to an Agreement and Plan of Merger, dated as of July 1, 2019, among G&W, DJP XX, LLC ("Parent") and MKM XXII Corp. ("Merger Sub"), Merger Sub was merged with and into G&W (the "Merger") with G&W surviving the Merger as a wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, upon completion of the Merger, each share of G&W common stock (other than certain excluded shares) was converted into the right to receive $112.00 in cash (the "Merger Consideration") and time-based vesting conditions of each unvested deferred stock unit, restricted stock unit, phantom stock unit, restricted share or similar stock right ("Stock Units") were deemed satisfied and accelerated in full and each Stock Unit was cancelled and entitled the holder to receive the Merger Consideration. F2: Included in the table above are a total of 2,275 Stock Units which were accelerated in connection with the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 30, 2019, in connection with the acquisition of Genesee & Wyoming Inc. ("G&W") by Brookfield Infrastructure and GIC, pursuant to an Agreement and Plan of Merger, dated as of July 1, 2019, among G&W, DJP XX, LLC ("Parent") and MKM XXII Corp. ("Merger Sub"), Merger Sub was merged with and into G&W (the "Merger") with G&W surviving the Merger as a wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, upon completion of the Merger, each share of G&W common stock (other than certain excluded shares) was converted into the right to receive $112.00 in cash (the "Merger Consideration") and time-based vesting conditions of each unvested deferred stock unit, restricted stock unit, phantom stock unit, restricted share or similar stock right ("Stock Units") were deemed satisfied and accelerated in full and each Stock Unit was cancelled and entitled the holder to receive the Merger Consideration.
F2: Included in the table above are a total of 2,275 Stock Units which were accelerated in connection with the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 09, 2025 Filed Jul 11, 2025 20:31 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 42,120 | $6.88 | $289,785.60 |
DisclosureSEC source: 0001104659-25-067431 · tm2520691-4_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2025 Filed Jul 8, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 6,986 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0001104659-25-066420 · tm2520047-1_4seq1.xml · derivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,208 Underlying: Common Stock · 6,986 shares Expires 2027-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| July 07, 2025 Filed Jul 8, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 6,986 | $6.88 | $48,063.68 |
DisclosureSEC source: 0001104659-25-066420 · tm2520047-1_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:15 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 23,400 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0001104659-25-055974 · tm2516959-1_4seq1.xml · derivative · entry 4 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,194 Underlying: Common Stock · 23,400 shares Expires 2027-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:15 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 18,993 | $61.52 | $1,168,494.94 |
DisclosureSEC source: 0001104659-25-055974 · tm2516959-1_4seq1.xml · nonDerivative · entry 3 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,929 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $61.33 to $61.62 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:15 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 4,407 | $60.93 | $268,515.43 |
DisclosureSEC source: 0001104659-25-055974 · tm2516959-1_4seq1.xml · nonDerivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 128,922 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $60.33 to $61.32 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:15 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 23,400 | $6.88 | $160,992.00 |
DisclosureSEC source: 0001104659-25-055974 · tm2516959-1_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 02:50 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 2,215 | $57.22 | $126,742.30 |
DisclosureSEC source: 0001104659-25-015325 · tm257103-8_4seq1.xml · nonDerivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,929 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 02:50 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 6,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-015325 · tm257103-8_4seq1.xml · derivative · entry 5 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,800 Underlying: Common Stock · 6,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. F5 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 02:50 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 6,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-015325 · tm257103-8_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,144 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 02:50 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Options (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $56.69 | $0.00 |
DisclosureSEC source: 0001104659-25-015325 · tm257103-8_4seq1.xml · derivative · entry 4 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2035-02-13 F4 · derivative.exercise_date: The stock options were granted on February 14, 2025. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 02:50 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 41,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-015325 · tm257103-8_4seq1.xml · derivative · entry 3 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,650 Underlying: Common Stock · 41,650 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:59 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 12 | $56.22 | $674.64 |
DisclosureSEC source: 0001104659-25-014273 · tm256729-3_4seq1.xml · nonDerivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,544 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:59 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 739 | $56.39 | $41,672.21 |
DisclosureSEC source: 0001104659-25-014273 · tm256729-3_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,556 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 11, 2025 Filed Feb 12, 2025 02:44 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 2,343 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-011674 · tm256299-1_4seq1.xml · derivative · entry 6 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,343 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. Read SEC document |
| February 11, 2025 Filed Feb 12, 2025 02:44 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 5 | $57.53 | $287.65 |
DisclosureSEC source: 0001104659-25-011674 · tm256299-1_4seq1.xml · nonDerivative · entry 4 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,295 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 11, 2025 Filed Feb 12, 2025 02:44 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,291 | $57.51 | $74,245.41 |
DisclosureSEC source: 0001104659-25-011674 · tm256299-1_4seq1.xml · nonDerivative · entry 3 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,300 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 11, 2025 Filed Feb 12, 2025 02:44 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 2,343 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-011674 · tm256299-1_4seq1.xml · nonDerivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 09, 2025 Filed Feb 12, 2025 02:44 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 4,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-011674 · tm256299-1_4seq1.xml · derivative · entry 5 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,062 Underlying: Common Stock · 4,062 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. Read SEC document |
| February 09, 2025 Filed Feb 12, 2025 02:44 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 4,062 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-011674 · tm256299-1_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 04, 2025 Filed Feb 5, 2025 02:27 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,678 | $59.43 | $99,723.54 |
DisclosureSEC source: 0001104659-25-009287 · tm255457-5_4seq1.xml · nonDerivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,186 F2 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 01, 2025 Filed Feb 5, 2025 02:27 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 4,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-009287 · tm255457-5_4seq1.xml · derivative · entry 3 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,850 Underlying: Common Stock · 4,925 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2025 Filed Feb 5, 2025 02:27 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 4,925 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-009287 · tm255457-5_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,864 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| March 19, 2024 Filed Mar 20, 2024 00:57 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 15,515 | $39.22 | $608,498.30 |
DisclosureSEC source: 0001104659-24-036319 · tm249308-6_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,939 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $39.04 to $39.22. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 00:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (Right to Buy) · Derivative | 80,400 | $0.00 Strike: $49.23 | $0.00 |
DisclosureSEC source: 0001104659-24-026156 · tm246920-3_4seq1.xml · derivative · entry 3 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,400 Underlying: Common Stock · 80,400 shares Expires 2034-02-15 F4 · derivative.exercise_date: The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 00:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 26,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-026156 · tm246920-3_4seq1.xml · derivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,400 Underlying: Common Stock · 26,400 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 00:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantCommon Stock | 33,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-026156 · tm246920-3_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,454 F1 · shares: The Issuer previously granted the Reporting Person an award of restricted stock units that vest based on the Issuer's satisfaction of certain performance objectives. On February 16, 2024, the Board determined that the performance condition had been satisfied. Read SEC document |
| February 13, 2024 Filed Feb 14, 2024 01:50 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 709 | $49.82 | $35,322.38 |
DisclosureSEC source: 0001104659-24-022540 · tm246165-5_4seq1.xml · nonDerivative · entry 4 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,704 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 01:50 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,209 | $51.38 | $62,118.42 |
DisclosureSEC source: 0001104659-24-022540 · tm246165-5_4seq1.xml · nonDerivative · entry 3 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,413 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 11, 2024 Filed Feb 14, 2024 01:50 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 2,344 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-022540 · tm246165-5_4seq1.xml · derivative · entry 6 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,343 Underlying: Common Stock · 2,344 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. Read SEC document |
| February 11, 2024 Filed Feb 14, 2024 01:50 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 2,344 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-022540 · tm246165-5_4seq1.xml · nonDerivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,622 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 01:50 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 4,063 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-022540 · tm246165-5_4seq1.xml · derivative · entry 5 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,124 Underlying: Common Stock · 4,063 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 01:50 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 4,063 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-022540 · tm246165-5_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,278 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:54 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 4,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010799 · tm245251-4_4seq1.xml · derivative · entry 3 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,775 Underlying: Common Stock · 4,925 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:54 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,616 | $45.06 | $72,816.96 |
DisclosureSEC source: 0001104659-24-010799 · tm245251-4_4seq1.xml · nonDerivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,215 F2 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:54 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 4,925 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-010799 · tm245251-4_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 21:15 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,500 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0001104659-24-000828 · tm2333854-2_4seq1.xml · derivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,594 Underlying: Common Stock · 10,500 shares Expires 2027-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock options is fully vested. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 21:15 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 10,500 | $6.88 | $72,240.00 |
DisclosureSEC source: 0001104659-24-000828 · tm2333854-2_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,906 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2023 Filed Dec 7, 2023 21:16 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0001104659-23-124302 · tm2332322-1_4seq1.xml · derivative · entry 6 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,094 Underlying: Common Stock · 20,000 shares Expires 2027-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options is fully vested. Read SEC document |
| December 06, 2023 Filed Dec 7, 2023 21:16 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 20,000 | $40.00 | $800,000.00 |
DisclosureSEC source: 0001104659-23-124302 · tm2332322-1_4seq1.xml · nonDerivative · entry 4 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,406 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2022. Read SEC document |
| December 06, 2023 Filed Dec 7, 2023 21:16 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 20,000 | $6.88 | $137,600.00 |
DisclosureSEC source: 0001104659-23-124302 · tm2332322-1_4seq1.xml · nonDerivative · entry 3 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,406 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 05, 2023 Filed Dec 7, 2023 21:16 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,026 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0001104659-23-124302 · tm2332322-1_4seq1.xml · derivative · entry 5 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,094 Underlying: Common Stock · 7,026 shares Expires 2027-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options is fully vested. Read SEC document |
| December 05, 2023 Filed Dec 7, 2023 21:16 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 7,026 | $35.06 | $246,359.66 |
DisclosureSEC source: 0001104659-23-124302 · tm2332322-1_4seq1.xml · nonDerivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,406 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $35.00 to $35.25. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 05, 2023 Filed Dec 7, 2023 21:16 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 7,026 | $6.88 | $48,338.88 |
DisclosureSEC source: 0001104659-23-124302 · tm2332322-1_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,432 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 24, 2023 Filed Nov 28, 2023 21:05 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,974 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0001104659-23-121648 · tm2331580-1_4seq1.xml · derivative · entry 3 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,120 Underlying: Common Stock · 10,974 shares Expires 2027-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options is fully vested. Read SEC document |
| November 24, 2023 Filed Nov 28, 2023 21:05 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 10,974 | $35.02 | $384,335.82 |
DisclosureSEC source: 0001104659-23-121648 · tm2331580-1_4seq1.xml · nonDerivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,406 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $35.00 to $35.28. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 24, 2023 Filed Nov 28, 2023 21:05 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 10,974 | $6.88 | $75,501.12 |
DisclosureSEC source: 0001104659-23-121648 · tm2331580-1_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:05 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $6.88 | $0.00 |
DisclosureSEC source: 0001104659-23-119091 · tm2330902-1_4seq1.xml · derivative · entry 3 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,094 Underlying: Common Stock · 12,000 shares Expires 2027-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock options is fully vested. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:05 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 12,000 | $30.38 | $364,573.20 |
DisclosureSEC source: 0001104659-23-119091 · tm2330902-1_4seq1.xml · nonDerivative · entry 2 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,406 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $30.00 to $30.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:05 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 12,000 | $6.88 | $82,560.00 |
DisclosureSEC source: 0001104659-23-119091 · tm2330902-1_4seq1.xml · nonDerivative · entry 1 Smith Hunter C · CIK 0001636385 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,406 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.